Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist

[1]  R. Couture,et al.  Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin‐diabetic rat , 2003, British journal of pharmacology.

[2]  Uday B Kompella,et al.  Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. , 2003, European journal of pharmacology.

[3]  P. Sirois,et al.  Inhibitory effect of a novel bradykinin B1 receptor antagonist, R-954, on enhanced vascular permeability in type 1 diabetic mice. , 2002, Canadian journal of physiology and pharmacology.

[4]  Z. Khalil,et al.  B1 and B2 antagonists and bradykinin-induced blood flow in rat skin inflammation , 2002, Inflammation Research.

[5]  W. Neugebauer,et al.  Kinin B1 receptor antagonists with multi-enzymatic resistance properties. , 2002, Canadian journal of physiology and pharmacology.

[6]  R. Couture,et al.  Kinin receptors in pain and inflammation. , 2001, European journal of pharmacology.

[7]  H. Kiyama,et al.  Constitutive nitric oxide synthase is associated with retinal vascular permeability in early diabetic rats , 2001, Diabetologia.

[8]  M. Carattino,et al.  The involvement of kallikrein-kinin system in diabetes type I (insulitis). , 1999, Immunopharmacology.

[9]  H. Higashida,et al.  Localization of B2 bradykinin receptor mRNA in the rat retina and sclerocornea. , 1999, Immunopharmacology.

[10]  E. Schremmer-Danninger,et al.  Identification and occurrence of mRNAs for components of the kallikrein-kinin system in human skin and in skin diseases. , 1999, Immunopharmacology.

[11]  R. Natarajan,et al.  Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. , 1999, Diabetes.

[12]  A. Rabinovitch.  An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. , 1998, Diabetes/metabolism reviews.

[13]  L. Chao,et al.  Expression and cellular localization of the kallikrein-kinin system in human ocular tissues. , 1996, Experimental eye research.

[14]  O. Catanzaro,et al.  Effects of B1 and B2 kinin receptor antagonists in diabetic mice. , 1996, Canadian journal of physiology and pharmacology.

[15]  G. Plante,et al.  Endothelial dysfunction in diabetes mellitus. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[16]  F. Marceau.  Kinin B1 receptors: a review. , 1995, Immunopharmacology.

[17]  S. Brain,et al.  Effect of a calcitonin gene‐related peptide antagonist (CGRP8–37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve , 1993, British journal of pharmacology.

[18]  R. Reed,et al.  Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. , 1993, Physiological reviews.

[19]  S. Leeman,et al.  Diminished Flare Response in Neuropathic Diabetic Patients: Comparison of Effects of Substance P, Histamine, and Capsaicin , 1987, Diabetes.

[20]  D. Regoli,et al.  Pharmacology of bradykinin and related kinins. , 1980, Advances in experimental medicine and biology.